Patents by Inventor Cecile Bougeret

Cecile Bougeret has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10851054
    Abstract: The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: December 1, 2020
    Assignees: BIOKINESIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Cecile Bougeret, Catherine Guillou, Julien Rouleau, Julie Rivollier, Denis Carniato
  • Publication number: 20190169124
    Abstract: The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.
    Type: Application
    Filed: January 25, 2019
    Publication date: June 6, 2019
    Inventors: CECILE BOUGERET, CATHERINE GUILLOU, JULIEN ROULEAU, JULIE RIVOLLIER, DENIS CARNIATO
  • Patent number: 10189782
    Abstract: The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: January 29, 2019
    Assignees: BIOKINESIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Cecile Bougeret, Catherine Guillou, Julien Rouleau, Julie Rivollier, Denis Carniato
  • Publication number: 20170233342
    Abstract: The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.
    Type: Application
    Filed: May 4, 2017
    Publication date: August 17, 2017
    Inventors: CECILE BOUGERET, CATHERINE GUILLOU, JULIEN ROULEAU, JULIE RIVOLLIER, DENIS CARNIATO
  • Patent number: 9643923
    Abstract: The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: May 9, 2017
    Assignees: BIOKINESIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Cécile Bougeret, Catherine Guillou, Julien Rouleau, Julie Rivollier, Denis Carniato
  • Publication number: 20160237042
    Abstract: Piperazinyl derivatives of formula (I) and their use as a drug, particularly for the treatment of cancer, are disclosed. Also disclosed are pharmaceutical compositions comprising the piperazinyl derivatives, and methods for synthesizing the piperazinyl derivatives.
    Type: Application
    Filed: April 22, 2016
    Publication date: August 18, 2016
    Inventors: Denis CARNIATO, Jean-Francois BRIAND, Mathieu GUTMANN, Olivier BUSNEL, Cécile BOUGERET, Benoit DEPREZ, Karine JAILLARDON
  • Publication number: 20150307450
    Abstract: The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.
    Type: Application
    Filed: December 6, 2013
    Publication date: October 29, 2015
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, BIOKINESIS
    Inventors: Cécile Bougeret, Catherine Guillou, Julien Rouleau, Julie Rivollier, Denis Carniato
  • Patent number: 8519188
    Abstract: The present invention relates to a compound of general formula (I): and also to the pharmaceutically acceptable salts thereof, to the isomers or isomer mixtures thereof in all proportions, in particular to an enantiomer mixture, and especially to a racemic mixture. The present invention also relates to the use of these compounds as a medicament, and in particular for the treatment of cancer, and also to the compositions containing them.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: August 27, 2013
    Assignee: Marc-Henry Pitty
    Inventors: Denis Carniato, Karine Jaillardon, Olivier Busnel, Mathieu Gutmann, Jean-Francois Briand, Benoit Deprez, Dominique Thomas, Cécile Bougeret
  • Publication number: 20110104162
    Abstract: The present invention relates to a compound of general formula (I): and also to the pharmaceutically acceptable salts thereof, to the isomers or isomer mixtures thereof in all proportions, in particular to an enantiomer mixture, and especially to a racemic mixture. The present invention also relates to the use of these compounds as a medicament, and in particular for the treatment of cancer, and also to the compositions containing them.
    Type: Application
    Filed: June 15, 2009
    Publication date: May 5, 2011
    Applicant: Cytomics Systems
    Inventors: Denis Carniato, Karine Jaillardon, Olivier Busnel, Mathieu Gutmann, Jean-Francois Briand, Benoit Deprez, Dominique Thomas, Cécile Bougeret
  • Publication number: 20100216160
    Abstract: An in cellulo method for the screening of proteasome activity-modulating agents, includes the following steps of: a) bringing into contact the candidate agent with the yeast cell expressing in their nucleus a fusion protein comprising: (i) a p21 polypeptide selected from the p21WAF1/Cip1 polypeptide and the p21[6KR]WAF1/Cip1 polypeptide; and (ii) at least one detectable protein; b) quantifying the first detectable protein in the yeast cells, at the end of at least one predetermined time interval after bringing into contact the candidate agent with the cells; c) comparing the value obtained at the step (b) with a control value obtained when the step (a) is performed in the absence of the candidate agent.
    Type: Application
    Filed: October 19, 2006
    Publication date: August 26, 2010
    Applicant: CYTOMICS SYSTEMS
    Inventors: Cécile Bougeret, Jean-Francois Briand, Patrick Zarzov, Dominique Thomas
  • Publication number: 20080057522
    Abstract: A method for screening agents modulating I?B? protein ubiquitination by a functional ubiquitin ligase protein complex containing ?-TrCP protein, the method including the following steps: (a) bringing into contact a candidate agent to be tested with recombinant yeast cells that express in their nucleus: (i) a fusion protein including the I?B? polypeptide and at least one first detectable protein; and (ii) a protein containing the ?-TrCP polypeptide; (b) quantifying the first detectable protein in the yeast cells, at the end of at least one predetermined period of time after bringing the candidate agent into contact with the cells; (c) comparing the result obtained in step (b) with a control result obtained when step (a) is carried out in the absence of the candidate.
    Type: Application
    Filed: March 15, 2005
    Publication date: March 6, 2008
    Inventors: Cecile Bougeret, Patrick Zarzov, Jean-Francois Briand, Dominique Thomas